Lysosomal storage disorders (LSD) are monogenic diseases, due to accumulation of specific undegraded substrates into lysosomes. LSD diagnosis could take several years, due to both poor knowledge of these diseases and shared clinical features. The diagnostic approach includes clinical evaluations, biochemical tests and genetic analysis of the suspected gene. In this study, we evaluated an LSD targeted sequencing panel as a tool capable to potentially reverse this 'classic' diagnostic route. The panel includes 50 LSD genes and 230 Conserved Intronic Fragments (CIF), obtained comparing the intronic sequences of 33 placental mammals. For the validation phase we analyzed 56 positive controls, 13 biochemically diagnosed and 9 undiagnosed patients. Disease-causing variants were identified in 66% of the positive control alleles and in 62% of the biochemically diagnosed patients. Three undiagnosed patients were diagnosed. Eight patients undiagnosed by the panel were analyzed by whole exome sequencing: for two of them the disease-causing variants were identified. Five patients, undiagnosed by both panel and exome analyses, were investigated through array CGH: one of them was diagnosed. CIF analysis performed in cases unresolved by the first-level analysis, evidenced no candidate intronic variants.
Introduction
Lysosomal storage disorders (LSD) are a group of more than 50 inherited rare disorders characterized by the accumulation of specific undegraded metabolites in the lysosomes. This overstorage is commonly caused by a deficient or absent activity of one of the many lysosomal hydrolases or, in a few cases, by the deficit of other non-enzymatic lysosomal proteins. Although singularly considered rare, the combined birth prevalence of LSD is estimated from 7.5 to 23.5 per 100,000 live births 1 . Clinical signs and symptoms may occur from the prenatal period to adulthood, and may develop at different progression rate, according to the pathology, leading to a wide spectrum of disease forms, from mild to extremely severe, that in most cases affect the neurological compartment 2 .
Generally, the diagnostic approach includes an accurate clinical evaluation, which leads to the formulation of a suspicion for one or more LSD. This is followed by biochemical tests, aimed to detect the storage products in body fluids or tissues, whose results may orient the following enzymatic analyses 3 . Finally, if an enzyme deficit is detected, genetic analysis is performed on the suspected gene. However, this diagnostic route presents several limitations. In fact, some LSD often share clinical signs and symptoms with other LSD or different disorders, thus their identification requires deep clinical expertise. Moreover, the above-mentioned biochemical methods are laborious, and they are often subject to high variability. Specifically, the execution of multiple enzyme assays may be expensive and fluorogenic substrates to perform them may present scarce availability. Finally, not all disorders present with elevated levels of storage products. All this may delay the diagnosis that, in some cases, could be very difficult and take several years or could be even unsuccessful 4, 5 .
In the last decade, the emergence of NGS technologies has proven to be an effective alternative to traditional techniques, both in research and in clinical settings, allowing the simultaneous interrogation of several genes in one single reaction, in a short time and at a reduced cost per base-pair with respect to Sanger sequencing 6 .
Given the limitations of the ''traditional'' diagnostic approach and the availability of the NGS technologies, it is conceivable that the previously described diagnostic route for LSD could be potentially reversed. An approach of targeting sequencing could be evaluated as the primary screening tool in the diagnosis of LSD, followed by biochemical and enzymatic tests aimed at confirming the molecular results. This alternative approach would potentially shorten the timing from the onset of first symptoms to the diagnosis, and considerably reduce costs.
In this study, we analyzed the feasibility of such a reversed approach through the evaluation of a targeted panel, including 50 LSD genes, as a potential diagnostic tool. Together with exons, promoters and UTRs, we included in the panel the most conserved intronic fragments of the analyzed genes, with the aim to widen variants search to these regions, in case of no appreciable results obtained through the analysis of the ''canonical'' regions.
Materials and methods

Genes selection and panel design
For the selection of the genes to be included in the panel we evaluated the Orphanet list of LSD [https://www.orpha.net/consor/cgi-bin/Disease.php?lng=EN; last access May 24 th , 2017], the SSIEM LSD list [http://www.ssiem.org/resources/IEC.asp; last access May 24 th , 2017] and the list of genes reported by Fernandez-Marmiesse and colleagues for their panel design 4 . Finally, we selected our list of 50 genes (Table 1) , by excluding from the whole LSD list both extremely rare disorders and disorders presenting a very peculiar phenotype.
The Ion AmpliSeq platform (Thermo Fisher Scientific, MA) was used for the design of a panel including the selected genes. The whole target sequence was 202.6 kb; for each gene the design included the protein-coding transcripts. For each transcript, the exons, a 50 bp flanking sequence on each side and both UTRs were given to the Ion Ampliseq Designer software as target sequence.
Moreover, we included the Conserved Intronic Fragments (CIF) obtained by: (a) identifying highly conserved sequences through the PhastCons tool 7 ; (b) merging and filtering identified regions based on length and mutual distance. We focused on a multiple alignment among 33 placental mammals and downloaded the corresponding scores from the UCSC Genome Browser portal (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/phastCons46way/; last access June 14 th , 2017). Filtering criteria were 0.85 minimum conservation score, 20 bp minimum length and 2 bp maximum distance between two fragments, to optimize coverage and number of sequences relatively to library and sequencing costs. For each gene, the 50 CIF with highest conservation score were included in the panel design. Importantly, we defined exonic and intronic regions by combining Ensembl and RefSeq annotations, to guarantee maximal coverage on functional sequences.
Samples selection and ethics statement
A total of 78 DNA samples were anonymously obtained and processed from the "Cell Line and DNA Biobank from Patients Affected by Genetic Diseases", member of the Telethon Network of Genetic Biobanks 8 and from some Clinical and Diagnostic Centers in Italy and in Croatia. 56 samples were from previously molecularly diagnosed patients (positive controls, PC) that were selected to represent most LSD and possibly their frequency 22 samples were evaluated as experimental samples: 13 belonged to patients that were diagnosed only through biochemical analysis and had not received a molecular confirmation of the enzymatic diagnosis (biochemically diagnosed patients, BD). 9 out of 22 samples were from patients with moderate to high suspicion of LSD, for whom a diagnosis had not yet been formulated (undiagnosed, UD). Informed consent for the targeted sequencing analysis was obtained for all the patients included in the study. Enrichment, library construction and sequencing 6 DNA library preparation was performed according to the Ion AmpliSeq Library Preparation protocol (Thermo Fisher Scientific) in combination with the Ion AmpliSeq Library kit, version 2.0.
After DNA quantification using Qubit dsDNA HS Assay Kit, the libraries were constructed starting from 10 ng of each DNA sample. The first step of targets amplification was performed by using our AmpliSeq LSD-Panel Primer pools. The amplicons were then indexed using the Ion Xpress Barcode Adapters kit and purified using AMPure XP magnetic beads (Beckman Coulter, Inc., Brea, CA). All reactions were performed according to the manufacturer's instructions. Each DNA library was then quantified by qPCR using the KAPA SYBR FAST qPCR kit (KAPABiosystems, MA).
Libraries were pooled at 100 pM, amplified by emulsion PCR and enriched, respectively with the One Touch and the ES machines (Thermo Fisher Scientific). For the Ion Proton sequencing, libraries were loaded into an Ion PI chip and sequenced using the Ion PI HiQ Sequencing 200 kit.
Sequencing data were analysed on a Torrent Server through the Torrent Suite Software (Thermo Fisher Scientific).
Runs had the following quality control metrics: 99% enrichment percentage, 22% polyclonal beads; 4% low-quality reads and 72% usable reads. Each library obtained about 300.000 reads with a mean length of 181 bp. Coverage data were obtained using the Coverage Analysis plugin.
Variants calling and prioritization
Alignment and variant calling were performed according to the Torrent Suite 5.0 analysis pipeline.
Alignment was performed with tmap (v. 5.0 with the following parameters: -J 25 --end-repair 15 -do-repeat-clip stage1 map4). Variant calling was performed with the Torrent Variant Caller (v. 5.0) with germline high stringency parameters, as supplied by the producer.
Variants analysis was performed by using QueryOR 9 , a platform for variants prioritization developed at CRIBI Biotechnology Center of the University of Padova. For each sample, variant analysis was split in 3 distinct queries aiming to prioritize missense, nonsense and sense variants (query 1), frameshift, inframe, stoploss and stopgain variants (query 2) and splicing-affecting variants (query 3). In case of no appreciable results obtained with the first three queries, an additional optional forth query was performed with the aim to prioritize the 5' UTR, 3' UTR and intronic variants ( Figure 1) . A preliminary analysis of positive controls through these 4 queries was performed to select the most suitable filters and their cut-off, capable to select the 'pathogenic' variants carried by PC samples. When no results were obtained through the above mentioned 4 queries, the same were re-launched removing the coverage filters, to detect uncovered or poor covered variants. In addition, if the output of a single query included more than one variant, during the manual variant evaluation, priority was given to alleles with the lowest frequency, to non-annotated alleles and to those presenting the highest pathogenic scores.
All identified variants were verified through IGV (Integrative Genomics Viewer, version 2. 
Analysis of Conserved Intronic Fragments (CIF)
The intronic variants located in the CIF included in the panel were filtered by QueryOR and analyzed by using different tools. Filtering criteria included frequency <0.01, association to a true major allele in the reference genome and deleterious substitution types. SPANR (Splicing-based Analysis of Variants; http://tools.genes.toronto.edu/; last access November 27 th , 2018) 10 was used to predict both intronic and exonic variants affecting RNA splicing; for each variant, which may be up to 300 nucleotides inside an intron, the tool computes a score for how strongly genetic variant affects RNA splicing. SPANR is based on a Bayesian machine learning model trained solely on RNAseq data relative to more than 10,000 exons with evidence of alternative splicing, thus disregarding disease annotations and population data. Simultaneously, variants falling in regulatory regions and predicted to have a deleterious impact were obtained through Ensembl VEP.
Variants validation and classification
The sequence variants identified in BD and UD patients were checked in Ensembl Analysis of WES data was performed using QueryOR 9 platform, following a flowchart similar to that used for the targeted sequencing panel data, setting coverage filters to >50X. In some cases, additional queries were performed setting specific GO (Gene Ontology), HPO (Human Phenotype Ontology) and/or DisGeNET terms as filters.
CGH array analysis
Five undiagnosed samples (UD2, UD4, UD5, UD7, UD8) were further analyzed through CGH array.
The analysis was conducted using the SurePrint G3 Human CGH Microarray Kit, 8x60K (Agilent Technologies, Santa Clara) with a resolution ≥ 100 kb. Data analysis was performed through the software Agilent Genomic Workbench 7.0. In the interpretation of the results, copy number variations (CNV) identified in loci not disease-associated at the time of the analysis, as well as alterations smaller than 100 kb, were not considered.
Results
Panel design and samples sequencing
The total target sequence length was 202.6 kb and included 50 LSD genes (Table 1) 
and 230
Conserved Intronic Fragments (CIF), with an average length of 40 bp. The panel design output was a 187.42 kb sequence covered by 1561 amplicons; the average amplicon length was 240 bp (median 257bp) with 93% (median 95.7%) of the whole target sequence covered. Considering only exons, their flanking sequences and UTRs, the target sequence coverage does not change significantly, being the uncovered sequences located in the coding sequence. Hence, the least covered genes resulted to be DNAJC5, CLN8, IDUA, NPC2 and HYAL1, whose sequences (CIF included) were covered for a percentage between 55 and 80% (Supplemental Table S1 ).
Considering only the coding sequence, the most uncovered gene is IDUA with 8 out of 14 exons being partially or totally uncovered. Any attempts to increase the coverage of these genes by modifying the setting during the phase of panel design did not result in any improvements. The same problem had been previously encountered by Fernandez-Marmiesse and coworkers 4 .
Samples sequencing was performed through the preparation of 4 independent libraries, followed by their sequencing by 4 separate runs. Minimum, maximum and average values per sample of total aligned bases, target base coverage depth, percentage of target sequence with coverage at 20X and 100X are reported in Supplemental Table S2 . Considering the real gene coverage compared to design coverage, moderate to slight variations were observed with the maximum increase with respect to design coverage for DNAJC55 gene (+33%) and the maximum decrease for ARSA gene (-21%) ( Supplemental Table S1 ). Variants analysis was carried out through a prioritization process performed by QueryOR platform 9 . The total number of known variants per samples group ranged from 63 to 359 with an average of 254 variants; the average number of novel variants per sample group was 7 (range: 2-24). For the three groups of samples analyzed, 'positive controls' (PC), 'biochemically diagnosed' (BD) and 'undiagnosed' (UD), we used the same flowchart for variant prioritization, consisting in performing a set of 4 queries, each capable of detecting a specific type of variants or group of variants ( Figure   1 ).
Variants analysis
Positive control samples analysis
An accurate preliminary choice of the most suitable filters capable to select the variants carried by the positive controls was performed: this selection led to the confirmation of the 4 queries set at the beginning of the study with only a slight modification, a small reduction of the CADD phred score from 15 to 10, to detect specific missense variants known to be pathogenic. The applied filters for each of the 4 queries are summarized in Figure 1 . For positive control samples, all disease-causing variants but few were detected applying the previously adjusted first three queries, being most variants located in the coding regions, in the nearest intron-exon boundaries or in canonical splicing sites. In addition, the ARSB intronic variant c.1213+6T>C, resulting in skipping of exon 6 (Authors' unpublished data), identified in samples PC2 and PC3, was detected only by applying the set of filters developed for intronic variants (query 4).
The analysis led to the identification of pathogenic variants in 66% of the PC alleles, with 31 samples in which both variants were identified and 11 in which only one variant was identified. In 14 PC samples no variants were detected; among them, 5 present with gross deletions or complex rearrangements: this kind of genetic modifications could not be detected by our panel. If we exclude the PC samples carrying large deletions and rearrangements, the percentage of identified alleles raises to 70%. Also, variants covered by low-quality reads, for example variants falling in specific regions of the genes harboring a pseudogene (i.e. IDS and GBA), were not retrieved by our variants search. Supplemental Table S3 reports the list of genotypes of positive control samples included in the present study.
The presence of large deletions encompassing one or more exons was confirmed by checking the degree of coverage of the affected exon(s) through the visualization tool IGV. This approach allowed the identification of large deletions only if present in homozygosis, differently from what reported by Fernandez-Marmiesse 4 . However, an attempt to apply the same approach for the detection of gross indels was made, with no statistically significant results, given the inter-and intra-run coverage variability between samples observed in our study.
Confirmation of biochemical diagnosis
Panel analysis led to the confirmation of previous enzymatic diagnoses for 8 cases out of 13, with the molecular characterization of 62% of the biochemically diagnosed patients. In two cases no variants were identified and in other two cases only one variant was found. In one subject, panel analysis results were not consistent with the biochemical data available. Table 2 reports the identified genotypes of the biochemically diagnosed subjects. Five patients carried homozygous variants, two were compound heterozygous and one was hemizygous. Most variants were missense, two were gross deletions, one was a small deletion and one a nonsense variant. The identification of gross deletions was possible by checking the reads coverage through IGV, as both deletions were carried in homozygosis status.
Four new variants, 1 missense in the GALNS gene, 1 nonsense in the SGSH gene, one gross deletion in the HEXB gene and one small deletion in the IDUA gene, were identified and are described below. In one case the panel result was not consistent with the biochemical analysis previously performed. Indeed, in a subject biochemically reported as affected by galactosialidosis (patient BD5) whose causative gene is CTSA, no variants in the CTSA gene were identified, instead we found two variants in the GNPTAB gene, which is associated with mucolipidosis II α/β, III α/β (ML II α/β, III α/β). One of the variants had been previously reported in the literature as pathogenic For the other two subjects, an MPS VI and a Krabbe patients, no variants were detected through the panel analysis.
New diagnoses achieved
The targeted panel was also tested on 9 undiagnosed patients (UD) who were referred to us with an LSD suspicion. For 7 of them, a specific or quite specific suspicion towards a particular LSD or class of LSDs was previously formulated. Moreover, for one of them (patient UD2), sequencing of the ARSB gene (MPSVI) and qPCR analysis for detection of exonic deletions had been previously performed with no results.
The LSD panel analysis led to the achievement of a diagnosis for 3 out of 9 patients. Table 3 reports the main clinical data available for these patients and the related genotype, where detected.
In a child suspected of MPSI/MPSII (patient UD1) a novel single-nucleotide insertion c.1390_1391insA [p.(Ser464Lysfs*15)] was found in hemizygosis in the IDS gene; the same variant was found in heterozygosis in the mother. The variant is not reported in ExAc and likely causes the alteration of the coding sequence from codon 464, with the insertion of a stop codon at position
478.
A diagnosis of ML II α/β, III α/β was achieved for a patient (patient UD3) whose clinical signs and symptoms were suggestive of mucolipidosis, but whose enzymatic data were ambiguous; thus, a deeper investigation, including molecular analysis, had not been conducted. Our analysis showed that the patient carried two previously described pathogenic variants in the GNPTAB gene: the 
Analysis of Conserved Intronic Fragments (CIF)
The analysis of CIF was performed to identify potentially dangerous variants located in intronic regions and was focused on samples from undiagnosed (UD) or biochemically diagnosed (BD) patients in which no variants had been found through the previous analysis. 345 intronic variants with frequency <0.01 or with no frequency (not annotated variants) filtered by QueryOR were uploaded in SpanR and in Ensembl VEP. Nine variants were selected by SpanR as potentially deleterious, but unfortunately none of them was carried by the mentioned UD or BD patients. The same intronic variants analyzed by VEP gave 61 candidate variants mapping in regulatory regions, two of which were carried by UD2 and BD1 samples in regions predicted as promoter and enhancer for LIPA and PSAP genes, respectively. However, their frequency, although below 1%, was relatively high (0.8 % and 0.56%), likely excluding their involvement as disease-causing variants in these two patients.
WES of undiagnosed patients
Six undiagnosed and 2 biochemically diagnosed patients, for whom the LSD panel could not identify pathogenic variants, and 1 BD patient for whom only one pathogenic variant had been identified, were further analyzed by whole exome sequencing (WES), to widen the analysis to the remaining coding sequences (Figure 2 ). Statistical data on coverage of WES runs are reported in Supplemental Table S4 . WES analysis was resolving for 2 patients: for subject BD10 we detected the second variant in the NPC1 gene; in patient UD6, for whom a Morquio-like disease was suspected, we detected in the TRPV4 gene the variant c.1781G>A [p.(Arg594His)], previously described in the literature 77 76 . For the other subjects analyzed the array CGH analysis did not identify any pathogenic CNV.
ACMG classification of variants
The variants detected in BD and UD patients were further analyzed using the criteria suggested by the ACMG 11 : results of this classification are reported in Supplemental Table S5 . As for the novel variants detected, three of them resulted 'likely pathogenic' (IDS:c.1390_1391insA; IDUA:c.793-10_798del; SGSH: c.1486C>T) while one resulted to be of 'uncertain significance' (GALNS:c.860C>G).
Discussion
The application of an NGS approach, like our LSD targeted panel, to the diagnosis of LSD could have several advantages with respect to the 'classic' diagnostic approach. It potentially reduces the timing of diagnosis which, in addition, could be achieved at lower costs, with respect to traditional approaches (enzymatic assays followed by specific Sanger sequencing analyses), considering that in some cases several enzymatic and/or genetic analyses are needed to achieve a defined diagnosis.
In this respect, our panel analysis revealed a previous misdiagnosis obtained by a biochemical approach: patient BD5 was suspected of galactosialidosis, however he carried two mutations in the GNPTAB gene, which is associated with mucolipidosis II α/β, III α/β. A similar case was recently reported by Gheldof 5 , who described a patient with a suspicion of galactosialidosis, later found to carry 2 known pathogenic variants in the GNPTAB gene. This is likely due to the peculiarity of mucolipidosis, which affects the activities of different enzymes tagged with mannose-6-phosphate molecule, and it is confirmed by Leroy et al 81 , who reported also infantile galactosialidosis among the disorders to consider in the differential diagnoses of ML II α/β, III α/β. Also, our undiagnosed patient UD3, finally defined as affected by ML II α/β, III α/β through the panel here proposed, had ambiguous enzymatic data, which did not fully suggest a mucolipidosis. This further stresses the advantages of an approach like a targeted panel which could be really useful in the differential diagnosis of LSD with overlapping clinical and biochemical phenotypes.
However, the results of our analysis showed a detection rate of 70% of the alleles for positive controls samples, if we do not consider large deletions and rearrangements, and 62% of the samples for biochemically diagnosed subjects, highlighting also the limitations of this diagnostic approach. The diagnostic yield for our PC samples with respect to the 'genetic classified patients'
of Fernandez-Marmiesse is lower 4 . This is due to the higher number of probands (about 3 times) analyzed by us and to the types of LSD tested; moreover, some of our subjects carried complex rearrangements or large deletions, not detectable by our platform of variants analysis. One of the technical limitations confirmed by this study is the poor or absent amplification of some specific regions, thus resulting as low-covered or uncovered regions, like several IDUA exons. In addition, some regions are covered by poor quality-reads: this is the case of repeated regions, due to genepseudogene sequences located one after the other, as in IDS and GBA genes. These two limitations could be overcome, in presence of a quite strong LSD suspicion, by filling the gaps of not fully covered genes by using classic PCR amplification followed by Sanger sequencing.
A further limitation is the poor ability, peculiar of the chosen NGS approach, to detect specific genetic alterations (complex rearrangements, CNVs). As for large deletions, this kind of alteration could be detected checking manually the coverage of the suspected gene: the degree of coverage of the examined region with respect to the same region in other samples of the same run could suggest the presence of a deletion in heterozygosis or could reveal one in homozygosis; however, in both cases, different molecular techniques should be used to confirm the suspected deletion(s), as well as to exclude potential allelic drop out events.
Given the LSD panel results, we decided to examine in-depth some unresolved cases, analyzing 9 patients through WES: this analysis led to resolution in 2 cases. The diagnostic yield of our WES analysis is similar to that reported in the literature (25-30%) in large-scale studies, in children with broad clinical presentations, in which WES was applied after multiple genetic and clinical investigations 82 . Also, it is comparable to that reported by Wang, who performed WES on 14 patients with suspicion of a lysosomal disorder, and found disease-causing or candidate diseasecausing variants in lysosomal genes in 4 cases and in non-lysosomal genes in 2 cases 83 . Indeed, most of our patients analyzed by WES had been previously biochemically tested for at least one or sometimes more lysosomal enzymes and in most cases with negative or ambiguous results; moreover, one of them had been genetically analyzed for MPSVI (ARSB gene).
This confirms that the ''classic'' diagnostic route could become a long or even endless odyssey for the patients and their relatives, and that several lysosomal disorders could remain undiagnosed after extensive genetic and biochemical investigations 4, 84 .
To increase the low detection rate, a deeper clinical characterization of LSD patients performed by a specialist is essential. In fact, these patients may show unspecific symptoms overlapping with other non-lysosomal disorders, as other neurometabolic or musculoskeletal disorders, that are sometimes not recognized by the specialists. In addition, the counseling of a geneticist would be useful to target the patients to the most appropriate genetic test. Once the test is performed, a close collaboration of the laboratory with the clinics would be very important to help addressing the variants filtration process towards the right direction, hopefully leading to the identification of the disease-causing variants. Moreover, when parents' DNA is available, analysis of the 'trio' would be highly preferable to singleton analysis, since this considerably increases the detection rate, as previously reported 85, 86 . Also, 'trio' analysis would be necessary to discriminate 'real' homozygosis from apparent homozygosis resulting from a deletion.
Our inclusion of the conserved intronic sequences (CIFs) was aimed at identifying possible intronic variants that presumably could be the cause of the disease, being located in highly conserved genomic regions. In fact, our results, as well as others reported in the literature 82, 83 , show that numerous disease-causing variants 'escape' the proposed NGS exomic approach of analysis.
However, unfortunately it is still very difficult to demonstrate the pathogenicity of the intronic variants, excluding the splicing ones; at the moment, only in silico predictions and evaluations based on alleles frequency can be performed, or mRNA analyses when RNA samples are available.
As a proof of this, recently Caciotti and colleagues identified a disease-causing deep intronic variant in GALNS gene in a Morquio A patient who had only one pathogenic allele characterized 87 .
Our CIF analysis could not detect candidate pathogenic intronic variants; however, we believe that the inclusion of these sequences in the panels may result useful in the future, representing a first step towards the analyses of these regions, whose function is still unknown. The choice of including only highly conserved intronic regions provides the advantage of limiting the analysis to the intronic regions likely important for the gene function, thus maintaining low the costs of the analysis.
Finally, an array CGH analysis was performed on five undiagnosed samples for which both panel and WES analyses resulted inconclusive. In one patient (UD5), array CHG revealed a deletion at q11.23 of chromosome 7: this alteration causes a developmental disorder called Williams syndrome 76 . Instead, for the other four patients the results excluded the presence of potentially pathogenic CNV in the subjects analyzed, further highlighting the complexity of the diagnosis for some LSD-suspected cases.
Conclusions
Targeted sequencing is an appealing approach to implement routine diagnostic strategy, given its low sequencing costs and short sequencing time. However, a good coverage must be assured and, when this is not reached, validation by Sanger sequencing needs to be carried out on the proband and on the parents as final step, also to exclude the presence of deletions in cases of homozygous variants finding. Moreover, the possibility to fill the gaps in the panel design must be guaranteed, especially in case of strong suspicion for a specific disease. Indeed, Sanger sequencing still remains a reliable sequencing technique and it should be considered an important support to NGS approaches especially for confirmation of variants with a coverage below the 'good' coverage threshold. Therefore, each laboratory should have a diagnostic flow-chart, providing appropriate molecular genetic tools to address the clinical suspicion.
We believe that the application of the panel or, in a near future, of a WES or WGS analysis as first or one of the first steps in diagnostic route, supported by a thorough phenotyping of the patients, and a tight collaboration between clinics and laboratory, could increase the yield of the diagnostic process of LSD, paving the way to a new 'reversed' approach.
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